Benchmarking the Average Drug

01 Oct 1997

Executive Summary

If you had only enough money to develop one drug, which therapeutic category would you choose? Based on data of average annual sales, anti-invectives are actually bigger than cardiovascular drugs, perhaps because the entire segment is buoyed by some new, more high priced products. But the best value may be anti-virals, which deliver high annual sales on average, with a relatively short-time to market.

Already Registered? Sign in to continue reading.

New to In Vivo? Start a free trial today!

Table
View full table

Topics

Industries
BioPharmaceutical
Subjects
Leadership

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical Leadership

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

IV000767

Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

IV000767

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Benchmarking the Average Drug

Executive Summary

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Benchmarking the Average Drug

Executive Summary

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert